1 April 2013BiotechnologyJaap Mannaerts

Biotech threats in the SPC system

At the time the supplementary protection certificates (SPC) regulation was draft ed, the legislator was well aware of the risk of SPCs becoming an instrument in ‘evergreening’ tactics—the ways in which pharmaceutical patent owners use the law and related regulatory processes to extend their IP rights.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotechnology

‘Doing more with less’: In-house counsel on budgets and strategy

22 October 2025 Chuck Scholtz, head of IP at Verdiva Bio, shares the pressures of global filing strategies on tight budgets, why there’s no ‘right way’ to manage IP, and how to get the best results from external counsel relationships.

Biotechnology

An update on patenting in Ukraine, Russia and Eurasia

2 September 2025 Erik Viik of Papula-Nevinpat looks at the dynamics that international applicants need to be aware of to secure and manage their patent rights across the region.

Biotechnology

Synthego clears rival’s patents from CRISPR market at Fed Circ

12 June 2025 Judges uphold PTAB’s finding that two Agilent patents are invalid | All claims of patents, which cover guide RNAs, found to be anticipated by prior art.

More features

UPC: A review of 2025 and what to expect in 2026

Mental health in IP: ‘We have a clear picture of the problem’

From Edwards to Insulet: Three key medical device cases of 2025

Edwards v Meril: Behind the UPC’s landmark medtech showdown

5 ways the USPTO director is changing US innovation

EU unveils sweeping pharma, biotech, and medical device reforms

WATCH: Clinical trials and their impact on patentability in Europe

WATCH: “Try and see” – an underestimated standard for obviousness before the EPO?

Biotech threats in the SPC system

More on this story

Editor's picks

Editor's picks

More features